LOGIN  |  REGISTER
Cue Biopharma

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

February 01, 2024 | Last Trade: US$23.12 0.18 -0.77

ATLANTA, Feb. 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 financial results will be released on Thursday, February 15, 2024 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13742847. 

The live webcast and replay can be accessed on the Investors section of the Artivion website at www.artivion.com and by selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investors section of the Artivion website.

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

  

Contacts:

 

Artivion

Gilmartin Group LLC

Lance A. Berry

Brian Johnston / Laine Morgan 

Executive Vice President &

Phone: 332-895-3222

Chief Financial Officer 

This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 770-419-3355

 
  

Stock Quote

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB